Followers | 12 |
Posts | 421 |
Boards Moderated | 0 |
Alias Born | 09/29/2010 |
Tuesday, October 17, 2017 11:45:41 PM
Partnership with Terumo for cardiac surgery use was announced Sept 12, 2016 for 6 European countries. On Dec 20, 2016 PR, Terumo launch sales into the 6 countries. They introduced the CytoSorb CPB Procedure Pack and have plans to introduce other kits. Success of this partnership could lead to future expansion. Along the same line as Frensius partnership, I'm thinking that there will be Terumo worldwide co-marketing agreement announcement soon. That includes partnering on the REFRESH II pivotal study. If this is the case, it would be nice to put the value of the study in the PR at $10-12 million since Dr Chan has let this information out a few times to really make the stock price pop. Enrolling patients into the cardiac study should run faster than for sepsis.
Three year partnership with Fresenius in critical care use was announced Dec 16, 2014 for 6 European countries. They initiated sales in the 6 countries in June 2016. On January 9 2017, they extended the 6 countries to 2019 and expanded the co-marketing agreement worldwide. It is expected that the co-marketing will commence worldwide starting in the second half of 2017. As part of the deal, FMC agrees to make guaranteed minimum quarterly orders and payments, evaluable every one and a half years. CytoSorbents talked about running some sepsis trials next year. (You may recall that there is an ongoing dosing study in EU as well) I think they will partner with Fresenius to run a pivotal study in the USA to gain FDA approval for the next generation CytoSorb XL. There is possiblity that the study results from the very first sepsis study (in Germany) or data from the CytoSorb registry will be accepted for the pilot study. The pilot study is small and its focused is mainly on safety of the device before continuing on to the pivotal study. You may recall that CytoSorb was declined under the EAP program. They need to run a large study for use in sepsis to be approved by the FDA.
If the potential partnerships are along the same line as the Aferetica one that was announced last month where it is paid for by the partner and CytoSorbents just provide the CytoSorb devices, the company will be saving considerable money. The value of the partnerships really need to be emphasized in the PR for investors to understand and in turn drive the stock price higher. Savings of $10-12 million for a 300-500 patient study really needs to be tooted! For two studies, that's a total $20-24 million that some big partners would be paying out of their accounts because they believe in the success of CytoSorb.
Recent CTSO News
- CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference • GlobeNewswire Inc. • 08/27/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2024 08:51:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2024 10:58:42 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2024 10:57:45 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/16/2024 09:28:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 09:12:04 PM
- CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 08/16/2024 08:05:00 PM
- CytoSorbents Reports Second Quarter 2024 Financial and Operational Results • GlobeNewswire Inc. • 08/13/2024 08:19:55 PM
- CytoSorbents Appoints Peter J. Mariani Chief Financial Officer • GlobeNewswire Inc. • 08/13/2024 08:18:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:04:32 PM
- CytoSorbents to Report Second Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 08/07/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:12:56 PM
- CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 08/01/2024 11:00:00 AM
- CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website • GlobeNewswire Inc. • 07/29/2024 12:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/26/2024 09:14:03 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/26/2024 09:11:21 PM
- CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress • GlobeNewswire Inc. • 07/17/2024 11:00:00 AM
- CytoSorbents Secures $20 Million Credit Facility • GlobeNewswire Inc. • 07/02/2024 11:00:00 AM
- CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan • GlobeNewswire Inc. • 06/24/2024 11:00:00 AM
- CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union • GlobeNewswire Inc. • 06/13/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:31:20 PM
- CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting • GlobeNewswire Inc. • 06/05/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:35:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 09:23:00 PM
- CytoSorbents Reports First Quarter 2024 Results • GlobeNewswire Inc. • 05/09/2024 08:17:23 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM